Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice-Reference-Cited by-同舟云学术

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice

Published:2006-08 Issue:8 Volume:3 Page:422-429
ISSN:1743-4270
Container-title:Nature Clinical Practice Urology
language:en
Short-container-title:Nat Rev Urol

Author:

Goetzl Manlio A,Holzbeierlein Jeffrey M

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

http://www.nature.com/articles/ncpuro0574.pdf

Reference33 articles.

1. Kelloff GJ et al. (2001) Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57 (4 Suppl 1): 46–51

2. Lieberman R (2003) Evolving strategies for prostate cancer chemoprevention trials. World J Urol 21: 3–8

3. Djavan B et al. (2004) Chemotherapeutic prevention studies of prostate cancer. J Urol 171: S10–S14

4. Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. New Engl J Med 349: 213–222

5. Huggins C et al. (1941) Studies on prostate cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral medications for central serous chorioretinopathy: a literature review;Eye;2019-09-16

2. Decision Analysis of Dutasteride Use for Patients With Negative Prostate Biopsy;Urology;2015-02

3. FINASTERIDE FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY;Retina;2011-04

4. Dutasteride: Novel milestones in prostate cancer chemoprevention;Drugs of Today;2011

5. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study;BMJ;2010-09-14